Quantcast
 
Search for: Search what?
Nov 9, 2009  
 Sections
Latest New Product News
Industry Market Trends
Green & Clean News
Association & Government News
Adhesives and Sealants
Agricultural and Farming Products
Architectural and Civil Engineering Products
Automatic ID
Chemical Processing and Waste Management
Cleaning Products and Equipment
Communication Systems and Equipment
Computer Hardware and Peripherals
Construction Equipment and Supplies
Controls and Controllers
Display and Presentation Equipment
Electrical Equipment and Systems
Electronic Components and Devices
Explosives, Armaments and Weaponry
Fasteners and Hardware
Fluid and Gas Flow Equipment
Food Processing and Preparation
Health, Medical and Dental Supplies and Equipment
HVAC
Labels, Tags, Signage and Equipment
Laboratory and Research Supplies and Equipment
Lubricants
Machinery and Machining Tools
Material Handling and Storage
Materials and Material Processing
Mechanical Components and Assemblies
Mechanical Power Transmission
Mining, Oil Drilling & Refining
Mounting and Attaching Products
Non-Industrial Products
Optics and Photonics
Packaging Products & Equipment
Paints and Coatings
Plant Furnishings and Accessories
Portable Tools
Printing and Duplicating Equipment
Retail and Sales Equipment
Robotics
Safety and Security Equipment
Sensors, Monitors and Transducers
Services
Software
Test and Measuring Instruments
Textile Industry Products
Thermal and Heating Equipment
Timers and Clocks
Transportation Industry Products
Vision Systems
Waste Handling Equipment
Welding Equipment and Supplies
 Press Releases
Products in the News
Company News
Mergers & Acquisitions
People in the News
Literature & Websites
 Resources
News Delivery Options
Browse Categories
Browse Companies
Mobile Edition
PR Resources
Licensing
Advertising
How to Write an effective Press Release
Trade Associations
Small Business Support
MEP
Advertisement

Catheter accesses hard-to-reach areas.


March 30, 2006 - Consisting of several hair-thin, stainless steel strands braided together, Asahi Tornus® delivers therapeutic, minimally invasive balloon catheters and stents to coronary arteries and other vessels blocked with chronic occlusions. Safety-release valve at proximal end indicates when device has reached maximum rotation, and tapered distal tip with radio-opaque marker provides optimal visualization in navigating difficult-to-access areas.

(Archive News Story - Products mentioned in this Archive News Story may or may not be available from the manufacturer.)

 See related product stories
Oxygenation Saturation Monitor uses fiber optics.
PVC Thoracic Catheters feature DEHP-free construction.
Bi-Directional Catheter helps treat irregular heart rhythms.
Plaque Removal Device helps treat peripheral artery disease.
Dual-Purpose Catheter can be used for SIS or AI procedures.
 See more product news in:
Health, Medical and Dental Supplies and Equipment
 Tools for you
del.icio.us DIGG  
Facebook Reddit
StumbleUpon Twitter
Print This Page E-Mail Story
Watch_Company  Save Story
View Company Profile
Company web site 
More news from this company

Advertisement
More Tools and information
Search for suppliers of
Catheters
Join the forum discussion at:
 Tools of the Trade
 Newsletters
Your Gateway to a Fast Changing World
Product News Alerts
Receive similar stories and other customized news to keep you in the know on the products shaping industry.
Subscribe Free Today
Subscribe   View Sample

Industry Market Trends
Has Got It
  • Latest developments
  • Trends
  • Best practices
  • Opinions & Commentary
Get Ahead. Get IMT.
Subscribe Free Today
Subscribe   View Sample
 See more related product stories:
Balloon Catheters address peripheral intervention needs.
Catheter offers 360° of encased needle tip protection.
Microcatheter System minimizes risks of kinking.
Catheter Aids facilitate introduction and navigation.


Abbott Launches New Specialty Catheter Technology in U.S.


Asahi Tornus(R) Device May Help Physicians Deliver Life-Saving Stents and Balloons to Dense Areas of Blockage in Coronary and Peripheral Vessels -

NEW YORK, Feb. 24 / -- Abbott today announced the introduction of a new specialty catheter designed to help physicians access areas of blockage in the coronary arteries and other vessels in the body that may be difficult to reach. Known as the Asahi Tornus(R) specialty catheter, the new stainless steel device is engineered to deliver therapeutic, minimally invasive balloon catheters and stents to vessels blocked with dense fibrous fatty plaque -- also known as chronic occlusions. The Tornus, which was cleared for marketing by the U.S. Food and Drug Administration, was launched at today's session of the Third International Chronic Total Occlusion Summit.

"The Tornus stainless steel catheter gives us more support for accessing a type of occlusion that for decades has represented a major frustration for interventionalists," said interventional cardiologist Gregg W. Stone, M.D., Division of Cardiology, Columbia University Medical Center and the Cardiovascular Research Foundation, New York. "Chronic occlusions have proven so resistant to conventional interventional technology that we refer to them as the 'last frontier' in interventional therapy."

Interventional therapy, also described as minimally invasive therapy, allows some patients with vessel disease to avoid surgery by undergoing treatment with balloon catheters or stents that are threaded to specific sites of vessel disease over therapeutic wires. Before a site of vessel blockage can be opened with a balloon or stent, it must be penetrated and crossed using a wire and support catheter. This is often referred to as "crossing the lesion."

"If a lesion cannot be crossed, it cannot be treated with minimally invasive therapy, and a patient may have to be referred for open heart surgery," said Dr. Stone. "About 15 percent of the patients we see have this type of a blockage. The Tornus catheter allows us to cross dense areas of vessel blockage so they can be successfully dilated and stented."

Support catheters are intended to provide additional assistance for physicians to access lesions with therapeutic wires. While most catheters are made of conventional plastic, the Tornus catheter is made of stainless steel to provide extra support during operator handling. The proprietary Tornus design consists of several hair-thin, stainless steel strands braided together to enhance flexibility and strength, along with a safety-release valve at the proximal end to indicate when the device has reached maximum rotation, and a specialized tapered distal tip with a radio-opaque marker for optimal visualization in navigating difficult-to-access areas. The device is available in two sizes: 2.1 Fr for accessing lesions that are more difficult to navigate and 2.6 Fr for circumstances requiring more support to push through the lesion.

"Through our partnership with Asahi, we are pleased to offer physicians a new option for treating challenging lesions," said David Van Meter, general manager, Coronary Technologies, Abbott Vascular. "The Tornus complements Abbott's broad line of Asahi guidewires, as well as our rapidly growing portfolio of devices for vascular interventionalists. These outstanding tools have earned high marks from the physicians who rely on them to deliver life-saving devices to patients with known areas of vessel disease."

The Tornus is manufactured by Japan-based Asahi Intecc Co., Ltd. Abbott has a licensing agreement with Asahi Intecc to distribute its guidewires in the U.S. and certain countries worldwide.

About Chronic Occlusions
Compared with areas of vessel narrowing (stenoses), chronic occlusions are typically longer and contain larger, denser masses of plaque. Chronic occlusions are generally characterized by dense, fibrous tissue that is often partially calcified and difficult to penetrate with conventional interventional technology tools. The severity of a chronic occlusion is determined by the degree of vessel narrowing, the rate of blood flow through the narrowing, and the age (chronicity) of the occlusion. Research reveals that approximately 30 percent of patients with coronary artery disease have at least one chronic occlusion.

About Abbott Vascular
Abbott Vascular, a division of Abbott, is transforming the treatment of vascular disease, combining the latest medical device innovations with world- class pharmaceuticals to advance medicine and improve patient care. Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products that are recognized internationally for their safety, effectiveness and ease of use in treating patients with vascular disease. Abbott Vascular is headquartered in Redwood City, Calif. For more information on Abbott Vascular, visit http://www.abbottvascular.com/ .

About Abbott
Abbott (NYSE:ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 60,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com/ .

Company Information:
Name: Abbott Laboratories
Address: 100 Abbott Park Rd., AP Abbott Park 5, Dept. 209
City: Abbott Park
State: IL
ZIP: 60064
Country: USA
Phone: 847-937-6578
FAX: 847-937-1708
http://www.abbott.com/


More New Product News from this company:
Molecular Diagnostic System speeds identification of pathogens.
Diagnostic Instrument automates immunoassay analysis.
Immunochemistry Analyzer boosts laboratory productivity.
Carotid Stent treats patients at risk of stroke.

Other News from this company:
Abbott Acquisition of Advanced Medical Optics Clears U.S. Antitrust Review
Abbott to Present at Cowen and Company Health Care Conference
Abbott to Present at Lehman Brothers Healthcare Conference
Abbott to Present at Merrill Lynch Healthcare Conference
Abbott Expands Its Growing Medical Device Business with Acquisition of Advanced Medical Optics (AMO)
Abbott to Present at JP Morgan Healthcare Conference
Abbott Announces New Products, Data and Positive Initiatives at 2007 AACC Annual Meeting
Abbott and Caprion Extend Partnership to Discover Antibody Targets for Cancer
Abbott Opens New Biotechnology Manufacturing Facility in Puerto Rico
Abbott to Sell Its Core Laboratory Diagnostics Business, Including Point of Care, to GE for $8.13 Billion
Private-Label Version of Abbott's XIENCE(TM) V Drug-Eluting Coronary Stent System Launches in Europe
Abbott's HUMIRA® (adalimumab) Receives FDA Approval for Inhibiting Structural Joint Damage and Improving Physical Function in Patients with Psoriatic Arthritis
Abbott Begins Early International Launch of XIENCE(TM) V Everolimus Eluting Coronary Stent System
Abbott Announces European Launch of Next-Generation Device Designed to Treat Patients at Risk of Stroke
Abbott Announces Continued Expansion of Vascular Operations in Ireland to Prepare for Drug Eluting Stent Manufacturing
Abbott Receives FDA Clearance for i-STAT® BNP Test to Diagnose Congestive Heart Failure
Abbott to Preview m2000(TM) Real-Time PCR Diagnostics System Designed to Provide Fast, Efficient Testing in the Molecular Lab
Abbott Reminds U.S. FreeStyle® and FreeStyle Flash® Blood Glucose Meter Users to Verify Units of Measure when they Test
Abbott and Dharmacon Collaborate to Develop New siRNA-Based Therapeutics
Abbott Enters Agreement with Cincinnati Children's Hospital to Develop Test to Detect Acute Kidney Failure



Click here for copyright permissions!
Copyright 2009 Thomas Publishing Company


 

Post a comment about this story

Name:
E-mail:
(your e-mail address will not be posted)
Comment title:
Comment:
 

Category Advertisements

ThomasNet News Advertisers



Visit Our New Web Site




Home  |  My ThomasNet News  |  Industry Market Trends  |  Submit Release  |  Advertise  |  Contact News  |  About Us
Brought to you by Thomasnet.com        Browse ThomasNet Directory

Copyright © 2009 Thomas Publishing Company
Terms of Use - Privacy Policy